April 8 Quick Takes: Hologic buying Mobidiag for nearly $800M; plus Biogen-Bio-Thera, Dicerna royalty sale, a SPAC for LumiraDx, Cidara-Janssen and Chi-Med’s $100M
Women’s health company Hologic Inc. (NASDAQ:HOLX) is acquiring Mobidiag Ltd., a Finnish-French maker of molecular diagnostics and instruments, for about $795 million, including $741 in cash and the assumption of net debt of about $81 million. Mobidiag develops and markets PCR-based tests for acute care conditions, such as GI and respiratory infections, antimicrobial resistance management, and healthcare-associated infections. It generated about $42 million in 2020 revenue.
Biogen licenses Bio-Thera biosimilar
Biogen Inc. (NASDAQ:BIIB) licensed exclusive rights outside Greater China and Taiwan to a biosimilar version of Actemra tocilizumab from Bio-Thera Solutions Ltd. (Shanghai:688177) for $30 million up front, plus potential milestones and royalties. The IL-6 receptor mAb, BAT1806, is in Phase III testing...